1060815-90-8

Basic information

• Product Name: 2-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine
• Synonyms: 2-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine;2-Chloro-5-iodo-7H-pyrrol...;2-chloro-5-iodo-7H-pyrrolo[2
• CAS NO: 1060815-90-8
• Molecular Formula: C₆H₃ClIN₃
• Molecular Weight: 279.46559
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 1060815-90-8.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Density: 2.284±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.68±0.50(Predicted)
• CAS DataBase Reference: 2-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine(1060815-90-8)
• EPA Substance Registry System: 2-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine(1060815-90-8)

Safety Data

• Hazardous Substances Data: 1060815-90-8(Hazardous Substances Data)

Usage

General Description

2-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine is a chemical compound with the molecular formula C7H3ClIN2. It is a heterocyclic organic compound containing a pyrrolopyrimidine ring system with chlorine and iodine substituents. 2-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine has potential applications in the fields of pharmaceuticals and agrochemicals due to its unique molecular structure and properties. It may also be used as a building block in the synthesis of various other organic compounds. The specific properties and potential uses of 2-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine depend on its synthesis and purification methods, as well as the context in which it is being used.

Upstream product

• 335654-06-3 2-chloro-7H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 1204400-82-7 C₁₃H₉ClIN₃O₂S 
• 1206454-52-5 C₁₂H₇ClIN₃O₂S 
• 1596334-85-8 N-{5-[2-amino-7-(2-hydroxy-1,1-dimethylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2-cyanophenyl}-2-(4-trifluoromethylphenyl)acetamide 
• 1596336-68-3 N-(5-{2-amino-7-[2-(tert-butyldimethylsilanyloxy)-1,1-dimethylethyl]-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl}-2-cyanophenyl)-2-(4-trifluoromethylphenyl)acetamide 
• 1596336-79-6 2-amino-4-{2-amino-7-[2-(tert-butyldimethylsilanyloxy)-1,1-dimethylethyl]-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl}benzonitrile 
• 1596336-81-0 4-[7-[1,1-dimethyl-2-(tetrahydropyran-2-yloxy)ethyl]-2-(4-methoxybenzylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl]-2-(4-methoxybenzylamino)benzonitrile 
• 1596337-11-9 4-{2-chloro-7-[1,1-dimethyl-2-(tetrahydropyran-2-yloxy)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl}-2-fluorobenzonitrile 
• 1596336-80-9 2-amino-4-[2-amino-7-(2-hydroxy-1,1-dimethylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl]benzonitrile 
• 1596335-33-9 N-[4-(2-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)pyridin-2-yl]-2-(4-chlorophenyl)acetamide 
• 1596335-37-3 N-{2-[2-amino-7-(2-hydroxy-1,1,-dimethylethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl]pyridin-4-yl}-2-(4-chlorophenyl)acetamide 
• 1402445-23-1 (5-aminopyridin-3-yl){7-(2-{[tert-butyl(dimethyl)silyl]oxy}-1,1-dimethylethyl)-2-[(2,4-dimethoxybenzyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}methanone 
• 1402438-74-7 PF-06273340 

Relevant articles and documents

Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma

Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors, especially liver cancer. With the resurgence of interest in irreversible inhibitors, efforts have been directed to the discovery of ir

The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain

The neurotrophin family of growth factors, comprised of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4), is implicated in the physiology of chronic pain. Given the clinical efficacy of anti-NGF monoclonal antibody (mAb) therapies, there is significant interest in the development of small molecule modulators of neurotrophin activity. Neurotrophins signal through the tropomyosin related kinase (Trk) family of tyrosine kinase receptors, hence Trk kinase inhibition represents a potentially druggable point of intervention. To deliver the safety profile required for chronic, nonlife threatening pain indications, highly kinase-selective Trk inhibitors with minimal brain availability are sought. Herein we describe how the use of SBDD, 2D QSAR models, and matched molecular pair data in compound design enabled the delivery of the highly potent, kinase-selective, and peripherally restricted clinical candidate PF-06273340.

NEW CHEMICAL COMPOUNDS

The present invention encompasses compounds of general formula (1) while the groups R4 to R7 and the units W, L, Qa and QH are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use as medicaments having the above-mentioned properties.